Acsis addresses future and current requirements for global source network Acsis Inc.

Relating to Acsis, companies have to adopt a fresh, cloud-based approach to gather all of the data being produced in their new source networks from both inner and external manufacturing and distribution procedures. Acsis goes on to explain how there are new technologies available to support today's multi-level, global source network. ‘It is important for companies to comprehend that in today's dynamic supply network environment, current ERP systems will be challenged to maintain with the speed of change required to achieve integration and presence across the source network,’ explained John DiPalo, Chief Strategy Officer for Acsis.

Aestus is excited to initiate our first clinical proof efficacy trial, said Tage Honore, President & CEO of Aestus. Our exclusive systems biology engine for discovery of novel targets in diseases of interest, followed by validation of the targets using substances developed for other indications, provides allowed us to advance quickly to phase 2 clinical studies . Related StoriesSpotting the symptoms of advanced prostate cancer: an interview with Brian TomlinsonBRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical SchoolAddressing quality of life needs in prostate malignancy: an interview with Professor Louis DenisThe Stage 2 clinical trial will test the efficacy of ATx08-001 in reducing pain in patients experiencing post-herpetic neuralgia, the lingering neuropathic discomfort following an outbreak of shingles.Aestus is excited to initiate our first clinical proof efficacy trial, said Tage Honore, President & CEO of Aestus. Our exclusive systems biology engine for discovery of novel targets in diseases of interest, followed by validation of the targets using substances developed for other indications, provides allowed us to advance quickly to phase 2 clinical studies . Related StoriesSpotting the symptoms of advanced prostate cancer: an interview with Brian TomlinsonBRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical SchoolAddressing quality of life needs in prostate malignancy: an interview with Professor Louis DenisThe Stage 2 clinical trial will test the efficacy of ATx08-001 in reducing pain in patients experiencing post-herpetic neuralgia, the lingering neuropathic discomfort following an outbreak of shingles.